Inhibition of mitogen-activated protein kinase phosphatase-1 (MKP-1) increases experimental stroke injury

Experimental Neurology

Volumn 261, Issue , 2014, Pages 404-411

  Liu, Lin ^a   Doran, Sarah ^a   Xu, Yan ^a   Manwani, Bharti ^a   Ritzel, Rodney ^a   Benashski, Sharon ^a   McCullough, Louise ^a   Li, Jun ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Cerebral ischemia; MAPK; MKP 1

Indexed keywords

2-BENZYLIDENE-3-(CYCLOHEXYLAMINO)-2,3-DIHYDRO-1H-INDEN-1-ONE; CYCLOHEXYLAMINE DERIVATIVE; ENZYME INHIBITOR; INDENE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; CASPASE 3; INTERLEUKIN 6; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN;

ANIMAL; BRAIN INJURIES; COMPLICATION; DEFICIENCY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; ENCEPHALITIS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETICS; INFARCTION, MIDDLE CEREBRAL ARTERY; KNOCKOUT MOUSE; MALE; METABOLISM; NEUROLOGIC EXAMINATION; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE EXACERBATION; ENZYME INHIBITION; FLOW CYTOMETRY; GENE DELETION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTRACELLULAR SIGNALING; ISCHEMIA; MICROGLIA; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; WILD TYPE;

ANIMALS; BRAIN INJURIES; CYCLOHEXYLAMINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DUAL SPECIFICITY PHOSPHATASE 1; ENCEPHALITIS; ENZYME ACTIVATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; INDENES; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MAP KINASE KINASE 4; MICE, KNOCKOUT; NEUROLOGIC EXAMINATION; P38 MITOGEN-ACTIVATED PROTEIN KINASES;

EID: 84905487944     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2014.05.009     Document Type: Article

References (28)

1. Barone F.C., Irving E.A., Ray A.M., Lee J.C., Kassis S., Kumar S., Badger A.M., Legos J.J., Erhardt J.A., Ohlstein E.H., Hunter A.J., Harrison D.C., Philpott K., Smith B.R., Adams J.L., Parsons A.A. Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia. Med. Res. Rev. 2001, 21:129-145.
2. Boutros T., Chevet E., Metrakos P. Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer. Pharmacol. Rev. 2008, 60:261-310.
3. Cui J., Zhang M., Zhang Y.Q., Xu Z.H. JNK pathway: diseases and therapeutic potential. Acta Pharmacol. Sin. 2007, 28:601-608.
4. Dorfman K., Carrasco D., Gruda M., Ryan C., Lira S.A., Bravo R. Disruption of the erp/mkp-1 gene does not affect mouse development: normal MAP kinase activity in ERP/MKP-1-deficient fibroblasts. Oncogene 1996, 13:925-931.
5. Eljaschewitsch E., Witting A., Mawrin C., Lee T., Schmidt P.M., Wolf S., Hoertnagl H., Raine C.S., Schneider-Stock R., Nitsch R., Ullrich O. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 2006, 49:67-79.
6. Farooq A., Zhou M.M. Structure and regulation of MAPK phosphatases. Cell. Signal. 2004, 16:769-779.
7. Horita H., Wada K., Rivas M.V., Hara E., Jarvis E.D. The dusp1 immediate early gene is regulated by natural stimuli predominantly in sensory input neurons. J. Comp. Neurol. 2010, 518:2873-2901.
8. Kapadia R., Tureyen K., Bowen K.K., Kalluri H., Johnson P.F., Vemuganti R. Decreased brain damage and curtailed inflammation in transcription factor CCAAT/enhancer binding protein beta knockout mice following transient focal cerebral ischemia. J. Neurochem. 2006, 98:1718-1731.
9. Koga S., Kojima S., Kishimoto T., Kuwabara S., Yamaguchi A. Over-expression of map kinase phosphatase-1 (MKP-1) suppresses neuronal death through regulating JNK signaling in hypoxia/re-oxygenation. Brain Res. 2012, 1436:137-146.
10. Koistinaho M., Koistinaho J. Role of p38 and p44/42 mitogen-activated protein kinases in microglia. Glia 2002, 40:175-183.
11. Korhonen R., Hömmö T., Keränen T., Laavola M., Hämäläinen M., Vuolteenaho K. Attenuation of TNF production and experimentally induced inflammation by PDE4 inhibitor rolipram is mediated by MAPK phosphatase-1. Br. J. Pharmacol. 2013, 169:1525-1536.
12. Kristiansen M., Hughes R., Patel P., Jacques T., Clark A., Ham J. Mkp1 is a c-Jun target gene that antagonizes JNK-dependent apoptosis in sympathetic neurons. J. Neurosci. 2010, 30:10820-10832.
13. Kuan C.Y., Whitmarsh A.J., Yang D.D., Liao G., Schloemer A.J., Dong C., Bao J., Banasiak K.J., Haddad G.G., Flavell R.A., Davis R.J., Rakic P. A critical role of neural-specific JNK3 for ischemic apoptosis. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:15184-15189.
14. Lawan A., Shi H., Gatzke F., Bennett A.M. Diversity and specificity of the mitogen-activated protein kinase phosphatase-1 functions. Cell. Mol. Life Sci. 2013, 70:223-237.
15. Liu Y., Shepherd E.G., Nelin L.D. MAPK phosphatases-regulating the immune response. Nat. Rev. Immunol. 2007, 7:202-212.
16. McCullough L.D., Tarabishy S., Liu L., Benashski S., Xu Y., Ribar T., Means A., Li J. Inhibition of calcium/calmodulin-dependent protein kinase kinase β and calcium/calmodulin-dependent protein kinase IV is detrimental in cerebral ischemia. Stroke 2013, 44:2559-2566.
17. Molina G., Vogt A., Bakan A., Dai W., Queiroz de Oliveira P., Znosko W., Smithgall T.E., Bahar I., Lazo J.S., Day B.W., Tsang M. Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages. Nat. Chem. Biol. 2009, 5:680-687.
18. Muda M., Boschert U., Dickinson R., Martinou J.C., Martinou I., Camps M., Schlegel W., Arkinstall S. MKP-3, a novel cytosolic protein-tyrosine phosphatase that exemplifies a new class of mitogen-activated protein kinase phosphatase. J. Biol. Chem. 1996, 271:4319-4326.
19. Nithianandarajah-Jones G.N., Wilm B., Goldring C.E., Müller J., Cross M.J. ERK5: structure, regulation and function. Cell. Signal. 2012, 24:2187-2196.
20. Nozaki K., Nishimura M., Hashimoto N. Mitogen-activated protein kinases and cerebral ischemia. Mol. Neurobiol. 2001, 23:1-19.
21. Patel A.R., Ritzel R., McCullough L.D., Liu F. Microglia and ischemic stroke: a double-edged sword. Int. J. Physiol. Pathophysiol. Pharmacol. 2013, 5:73-90.
22. Piao C.S., Kim J.B., Han P.L., Lee J.K. Administration of the p38 MAPK inhibitor SB203580 affords brain protection with a wide therapeutic window against focal ischemic insult. J. Neurosci. Res. 2003, 73:537-544.
23. Pouliot M., Serhan C.N. Lipoxin A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor-alpha-initiated neutrophil responses and trafficking: novel regulators of a cytokine-chemokine axis relevant to periodontal diseases. J. Periodontal Res. 1999, 34:370-373.
24. Rininger A., Dejesus C., Totten A., Wayland A., Halterman M.W. MKP-1 antagonizes C/EBP β activity and lowers the apoptotic threshold after ischemic injury. Cell Death Differ. 2012, 19:1634-1643.
25. Tait S.W., Green D.R. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat. Rev. Mol. Cell Biol. 2010, 11:621-632.
26. Taylor D.M., Moser R., Régulier E., Breuillaud L., Dixon M., Beesen A.A., Elliston L., Silva S.M.F., Kim J., Jones L., Goldstein D.R., Ferrante R.J., Luthi-Carter R. MAP kinase phosphatase 1 (MKP-1/DUSP1) is neuroprotective in Huntington's disease via additive effects of JNK and p38 inhibition. J. Neurosci. 2013, 33:2313-2325.
27. Yingqian H., Parakalan R., Eng-Ang L., Dheen S.T. Dexamethasone inhibits the Nox-dependent ROS production via suppression of MKP-1-dependent MAPK pathways in activated microglia. BMC Neurosci. 2011, 12:49.
28. Zhao Q., Wang X., Nelin L.D., Yao Y., Matta R., Manson M.E. MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock. J. Exp. Med. 2006, 203:131-140.